Systematic review: Treatment of chronic hepatitis B virus infection by pegylated interferon

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2005, Pages 519-528

  Hui, A Y ^a   Chan, H L Y ^a   Cheung, A Y K ^b   Cooksley, G ^c   Sung, J J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ASIAN; CHRONIC HEPATITIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; GENE MUTATION; HEADACHE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION; MEDLINE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THYROID DISEASE; TREATMENT WITHDRAWAL;

ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS;

EID: 25444528728     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02616.x     Document Type: Review

References (26)

1. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med 2004; 351: 2832-8.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-41.
3. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47-58.
4. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24 (Suppl. 1): 17-21.
5. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet 2003; 362: 2089-94.
6. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-23.
7. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
8. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527-32.
9. Fung SK, Lok AS. Management of hepatitis B patients with antiviral resistance. Antivir Ther 2004; 9: 1013-26.
10. Cooksley WG. Treatment with interferons (including pegylated interferons) in patients with hepatitis B. Semin Liver Dis 2004; 24 (Suppl. 1): 45-53.
11. Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004; 24 (Suppl. 2): 97-104.
12. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305.
13. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
14. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-50.
15. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-9.
16. Lau G, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
17. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a (40 kd) (Pegasys) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. Hepatology 2004; 40: 171A.
18. Lau G, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a (40 kd) (Pegasys) versus peginterferon alfa-2a plus lamivudine versus lamivudine in HBeAg-positive chronic HBV: effect of previous treatment and drug exposure on sustained response. J Hepatol 2005; 42 (Suppl. 2): 15.
19. Cooksley G, Manns M, Lau G, et al. Effect of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys) in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol 2005; 42 (Suppl. 2): 30.
20. Hadziyannis S, Lau G, Marcellin P, et al. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alfa-2a (40 kDa) (Pegasys). J Hepatol 2005; 42 (Suppl. 2): 178.
21. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
22. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828-53.
23. Thomas HC, Lok AS, Carreno V, et al. Comparative study of three doses of interferon-alpha 2 a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat 1994; 1: 139-48.
24. Lok AS, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.
25. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-8.
26. Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antivir Ther 2004; 9: 491-7.